The firm missed the Wall Street estimates on the top and bottom lines, and it lowered its EPS and adjusted EPS guidance for full-year 2018.
The companies will comarket Ultivue's UltiMapper assays with Leica's Bond Rx research staining platform for research applications.
Using SNP profiles, gut microbe metagenomics, and other data, researchers identified host and microbe factors influencing circulating levels of CVD markers.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The guidelines are the first to attempt to specify which drugs are appropriate to test for routinely, guideline authors say.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.